BLACK DIAMOND THERAPEUTICS, INC. Financials Black Diamond Therapeutics, Inc.
Equities
BDTX
US09203E1055
Biotechnology & Medical Research
|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.815 USD | +1.58% |
|
-1.44% | +70.82% |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 1,154 | 193.1 | 65.46 | 145.1 | 249 | - | - |
| Enterprise Value (EV) 1 | 838.6 | -16.69 | -57.35 | 145.1 | 249 | 249 | 249 |
| P/E ratio | -15.6 x | -1.54 x | -0.71 x | -1.49 x | -3.23 x | -2.84 x | -2.67 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - | - | 64 x |
| EV / Revenue | - | - | - | - | - | - | 64 x |
| EV / EBITDA | -16,595,135 x | -1,524,466 x | -709,045 x | - | - | - | - |
| EV / FCF | -22.1 x | -1.88 x | -0.77 x | - | -3.41 x | -2.63 x | -1.98 x |
| FCF Yield | -4.53% | -53.3% | -130% | - | -29.3% | -38% | -50.4% |
| Price to Book | 3.76 x | 0.98 x | - | - | - | - | - |
| Nbr of stocks (in thousands) | 35,996 | 36,229 | 36,366 | 51,635 | 52,530 | - | - |
| Reference price 2 | 32.05 | 5.330 | 1.800 | 2.810 | 4.740 | 4.740 | 4.740 |
| Announcement Date | 3/25/21 | 3/17/22 | 3/9/23 | 3/12/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | 3.893 |
| EBITDA | -29.28 | -69.52 | -126.7 | -92.32 | - | - | - | - |
| EBIT 1 | -29.33 | -69.57 | -126.9 | -92.83 | -86.46 | -85.73 | -112.4 | -138.2 |
| Operating Margin | - | - | - | - | - | - | - | -3,548.81% |
| Earnings before Tax (EBT) 1 | -35.26 | -67.25 | -125.6 | -91.17 | -82.44 | -80.88 | -104.1 | -123.3 |
| Net income 1 | -35.26 | -67.25 | -125.6 | -91.17 | -82.44 | -81.62 | -109.9 | -135.4 |
| Net margin | - | - | - | - | - | - | - | -3,479.09% |
| EPS 2 | -16.99 | -2.050 | -3.470 | -2.520 | -1.880 | -1.468 | -1.670 | -1.772 |
| Free Cash Flow 1 | -24.7 | -52.29 | -102.9 | -85.27 | - | -73 | -94.5 | -125.5 |
| FCF margin | - | - | - | - | - | - | - | -3,223.73% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 3/24/20 | 3/25/21 | 3/17/22 | 3/9/23 | 3/12/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA | -25.96 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -26.08 | -25.68 | -23.17 | -22.12 | -21.85 | -21.56 | -20.03 | -24.01 | -20.86 | -20.25 | -21.4 | -21.79 | -22.25 | -27.49 | -29.8 |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -25.87 | -25.51 | -22.93 | -21.65 | -21.08 | -20.88 | -19.15 | -23.01 | -19.41 | -18.22 | -20.38 | -20.88 | -21.4 | -25.06 | -27.05 |
| Net income 1 | -25.87 | -25.51 | -22.93 | -21.65 | -21.08 | -20.88 | -19.15 | -23.01 | -19.41 | -18.22 | -20.65 | -21.06 | -21.5 | -28.37 | -30.36 |
| Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS 2 | -0.7100 | -0.7000 | -0.6300 | -0.6000 | -0.5900 | -0.5700 | -0.5200 | -0.4500 | -0.3400 | -0.3500 | -0.3867 | -0.3683 | -0.3667 | -0.4450 | -0.4675 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/17/22 | 5/11/22 | 8/9/22 | 11/8/22 | 3/9/23 | 5/9/23 | 8/11/23 | 11/6/23 | 3/12/24 | 5/9/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | - | 315 | 210 | 123 | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -24.7 | -52.3 | -103 | -85.3 | - | -73 | -94.5 | -126 |
| ROE (net income / shareholders' equity) | - | -51.6% | -49.9% | - | - | - | - | - |
| ROA (Net income/ Total Assets) | -33.6% | -27.6% | -43.5% | - | - | - | - | - |
| Assets 1 | 105.1 | 244 | 288.7 | - | - | - | - | - |
| Book Value Per Share | -2.260 | 8.530 | 5.410 | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | 0.02 | - | 2.71 | 0.19 | - | - | - | 0.97 |
| Capex / Sales | - | - | - | - | - | - | - | 24.99% |
| Announcement Date | 3/24/20 | 3/25/21 | 3/17/22 | 3/9/23 | 3/12/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
4.74
USD
Average target price
12.6
USD
Spread / Average Target
+165.82%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +68.68% | 249M | |
| +10.79% | 116B | |
| +11.65% | 106B | |
| -6.20% | 23.89B | |
| -2.91% | 21.58B | |
| -10.90% | 18.96B | |
| -13.41% | 16.33B | |
| -40.50% | 16.96B | |
| +6.64% | 14.14B | |
| +31.84% | 12.02B |
- Stock Market
- Equities
- BDTX Stock
- Financials Black Diamond Therapeutics, Inc.
